• Users Online: 196
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
SHORT COMMUNICATION
Year : 2016  |  Volume : 14  |  Issue : 1  |  Page : 2-5

The Durazo technique is beneficial in Egyptian liver transplant programs


Visiting Assistant Project Scientist, Transplant Hepatology at UCLA and Consultant Hepatologist, Al-Azhar School of Medicine Asuit, Egypt

Date of Submission11-Nov-2015
Date of Acceptance12-Nov-2015
Date of Web Publication18-Apr-2016

Correspondence Address:
Abd Elrazek M Ali Hussein
Visiting Assistant Project Scientist Liver Surgery and Liver Transplant, UCLA
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1687-1693.180456

Rights and Permissions
  Abstract 

For nearly four decades, the American people have partnered with the people of Egypt to promote an environment where all groups in Egyptian society – including women and minorities – can lead healthy, productive lives. USAID's program in Egypt, helped scientists and researchers collaborate with American universities aiming to learn about modern American scientific innovations. I was lucky that I have collaborated with one of the most premier USA universities in Hepatology and Liver surgery; UCLA, where I can apply all the liver new techniques I have learned in UCLA in Egypt. Durazo technique is one of very interesting method-post liver transplant, would decrease morbidities and mortalities not only in USA and Egypt, but also Globally.

Keywords: Durazo, Egypt, ERCP, liver transplant, UCLA


How to cite this article:
Ali Hussein AM. The Durazo technique is beneficial in Egyptian liver transplant programs. Al-Azhar Assiut Med J 2016;14:2-5

How to cite this URL:
Ali Hussein AM. The Durazo technique is beneficial in Egyptian liver transplant programs. Al-Azhar Assiut Med J [serial online] 2016 [cited 2017 Oct 17];14:2-5. Available from: http://www.azmj.eg.net/text.asp?2016/14/1/2/180456


  Introduction Top


Endoscopic treatment has almost totally replaced surgical treatment of bile duct stones. In addition, a variety of benign and malignant conditions such as iatrogenic strictures [after cholecystectomy/after liver transplantation (LT)], primary sclerosing cholangitis (PSC), papillary adenoma, or malignant tumors of the bile duct or pancreas are now amenable to endoscopic treatment. In the early years, ERCP served as a diagnostic and therapeutic tool. With the development of noninvasive imaging alternatives, ERCP became a purely therapeutic procedure. The use of ERCP appears to be increasing with time. A population-based study from Olmstead County in the USA revealed that the average utilization of ERCP increased from 58 to 105 ERCPs per 100 000 persons-years over a 10-year period from 1997 to 2006. Biliary complications (bile duct strictures, leaks, and stones) following LT can be categorized as early (within 4 weeks) or late [1],[2],[3],[4],[5],[6],[7],[8],[9],[10],[11]. Biliary strictures after LT can be further divided into anastomotic, nonanastomotic, and diffuse intrahepatic strictures [Table 1]. Other complications such as bile casts, sphincter of Oddi dysfunction, mucocele, and hemobilia are rare, and most of them can be managed successfully with endoscopic retrograde cholangiography. In recent years, advanced ERCP techniques have become standard in many centers worldwide [12],[13],[14],[15],[16],[17],[18],[19],[20]. David Geffen School of Medicine at UCLA, USA, has been a highly reputed center for LT since 1984 when Ronald Busuttil (The Fujiyama of UCLA Liver Transplant Program) founded the Liver Transplant Program at UCLA. It has since grown to become one of the largest liver transplant centers in the world. In 2013 the UCLA liver transplant team presented the world's largest reported single-institution experience with 5347 orthotropic liver transplants (OLTs) performed between 1984 and 2012, with overall, 1-, 5-, 10-, and 20-year patient and graft survival estimates of 82, 70, 63, 52%, and 73, 61, 54, and 43%, respectively. Recipient survival was best in children with biliary atresia and worst in adults with malignancy [21]. However, biliary complications are an important cause of morbidity and mortality in LT recipients. Here, we will shed light on the recent and advanced techniques of ERCP after LTs performed at UCLA.
Table 1: Biliary complications after liver transplantation would be managed by ERCP

Click here to view



  Diagnosis and Advanced Techniques Top


Biliary complication is usually first suspected in asymptomatic LT recipients who have unexplained elevations of serum aminotransferases, bilirubin, alkaline phosphatase, and γ-glutamyl transferase levels. Occasionally, some patients have nonspecific symptoms such as fever, general malaise and anorexia, right upper-quadrant abdominal pain (especially with bile leaks), itching, jaundice, and bile ascites. Exposure of the peritoneum and other visceral structures to bile usually results in abdominal pain. However, pain may be subtle in other patients because of immunosuppressant medications and anatomic hepatic denervation.

The initial evaluation should include conventional two dimensional ultrasound (US) with a Doppler evaluation of the hepatic and portal vessels to rule out any vascular occlusion. If hepatic artery stenosis or occlusion is suspected by Doppler US, hepatic angiography is usually indicated before other tests. Further, the liver biopsy need not exclude rejection, if there is biliary dilation and/or the presence of common bile duct stones/casts, strictures or evident leaks. In addition, histologic features of bile duct obstruction can sometimes be misleading and confused with rejection or recurrent hepatitis C virus. However, the absence of bile duct dilation on US should not preclude further evaluation with more sensitive techniques in patients in whom there is clinical suspicion of biliary tract complications. When diagnosis of biliary stricture or leak is considered, ERCP has the best sensitivity and specificity for diagnosis compared with other noninvasive investigation modalities such as computed tomography (CT) or magnetic resonance cholangio-pancreatography (MRCP), in addition to its therapeutic options.

One trial found that performing an ERC only when there was evidence of a bile duct obstruction or leak on imaging studies, laboratory tests, or liver biopsy led to a high-yield study [22].


  Techniques Top


Maximal stent therapy

The maximal stenting protocol for anastomotic biliary strictures (ABSs) is rarely associated with ABS recurrence and is conducive to less frequent stent exchange and therefore fewer ERCPs compared with conventional treatment [23]. We followed Dr Francisco A. Durazo, Chief of Transplant Hepatology at UCLA, for around 6 months to learn his outstanding techniques for patients with biliary complications after OLT. Initiation of moderate to deep sedation was induced with intravenous meperidine or fentanyl and midazolam. ERCP was performed with a therapeutic side-viewing endoscope (TJF 160; Olympus Optical Co. Ltd, Center Valley, Pennsylvania) in the conventional manner with standard accessories. The endoscope was passed with ease. Dr Durazo always performs the short shaft endoscopic technique with minimal air inflation in the stomach. After selective cannulation of the common bile duct, a cholangiogram was obtained to evaluate the biliary system. Once the ABS was identified, a guidewire was passed through it into the donor's ducts to perform dilation. According to the Durazo recommendation, the implementation of maximal stenting depended on the length of time since OLT and the dose of steroids: if the patient had undergone LT within the past 3 months or was taking more than 5 mg of prednisone per day, dilation was performed with a 10-Fr biliary dilator (Soehendra dilator; Cook Endoscopy, Winston-Salem, North Carolina, USA), and a 10-Fr stent was placed for 12 weeks. During a subsequent ERCP, the stent was removed, and balloon dilation was performed (balloon dilator; Cook Endoscopy) with a balloon 6–10 mm in diameter, according to the size of the donor's and recipient's ducts (the duct with the smaller diameter, donor's or recipient's, determined the diameter of the balloon), for 1 min. When balloon dilation was completed, a sphincterotomy was performed following the standard technique (Ultratome; Boston Scientific, Natick, Massachusetts, USA), and a maximal number up to 10 stents of 8.5–11.5 Fr (Cotton-Leung; Cook Endoscopy) were placed across the anastomosis ([Figure 1]). We concluded that the maximal stenting technique (Francisco Durazo technique) for ABSs would be highly beneficial in our Egyptian liver transplant programs, in which only living donor operations are performed and there is a probability of biliary complications. In addition, following up patients at UCLA showed us that the technique is very effective, safe, rarely associated with ABS recurrence, and conducive to less frequent stent exchange and therefore fewer ERCPs compared with our conventional techniques.
Figure 1: Many stents emerging from an ampulla of a transplanted patient presented with biliary stricture after orthotropic liver transplant (OLT); the Durazo technique is highly beneficial in Egyptian living donor liver transplantation (LDLT) programs because many biliary complications are reported in LDLT than in OLT because of anastomotic stricture.

Click here to view


Intraductal cooling through a nasobiliary tube during radiofrequency

We have observed the safety and efficacy of intraductal perfusion of chilled 5% dextrose in water (D5W) through an endoscopic nasobiliary tube for the prevention of thermal bile duct injury in patients undergoing percutaneous radiofrequency ablation of central liver tumors [24]. The technique is especially beneficial for those awaiting LT as there is no other solution to prevent ductal injury during RFA in these patients if their tumor is close to a biliary ductal branch; the technique mentioned above would help prevent thermal biliary injury during radiofrequency ablation of central liver tumors without increasing the rates of local tumor progression.

IG4-related disease investigations

Immunoglobulin IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder that is often characterized by the presence of a pseudotumor with locally expansive behavior. Such patients are often misdiagnosed initially as having a malignancy. Other patients present with systemic symptoms including fever, malaise, and weight loss. These different presentations, which are only some of the ways in which IgG4-RD can present, are not mutually exclusive, especially in patients previously diagnosed with PSC. According to the Durazo recommendations we have to rule out IGg4-RD in each patient with PSC diagnosis and/or those with biliary stricture of unknown etiology using both Ig4 laboratory test and ductal biopsy using SpyGlass endoscopy [Figure 2], [Figure 3], [Figure 4]. Histologically, IGg4-RD is characterized by the typical histopathological features of a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, a high ratio of IgG4-positive to IgG-positive cells, storiform fibrosis (cellular fibrosis organized in an irregular whorled pattern), obliterative phlebitis, and variable presence of eosinophils. The clinical presentation depends on the involved tissues. However, the histopathologic findings seem to be similar regardless of location, and diagnosis is therefore based on histopathology and immunohistochemistry. In addition, patients often respond well to corticosteroid and immunosuppressive therapy [25],[26].
Figure 2: Intraductal apperance of common bile duct (CBD) and hepatic ducts; left and right using SpyGlass endoscopy.

Click here to view
Figure 3: SpyGlass appears from the channel of ERCP. Note the biopsy forceps.

Click here to view
Figure 4: SpyGlass (Boston Scientific), useful for demonstration of intraductal pathology. ABS; Anastomotic Biliary Stricture (s), ERCP; Endoscopic Retrograde Cholangio-pancreatography, RFA; Radio-Frequency Ablation.

Click here to view


Acknowledgements

Dr Abd Elrazek M. Ali Hussein and Al Azhar School of Medicine at Assiut, Assiut, Egypt thank Professor Dr Francisco A. Durazo, the Director of Transplant Hepatology at David Geffen School of Medicine, UCLA, for his scientific support and prompt help.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Stratta RJ, Wood RP, Langnas AN, Hollins RR, Bruder KJ, Donovan JP, et al. Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Surgery 1989; 106:675.  Back to cited text no. 1
    
2.
Pfau PR, Kochman ML, Lewis JD, Long WB, Lucey MR, Olthoff K, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000; 52 (1):55-63.  Back to cited text no. 2
    
3.
Greif F, Bronsther OL, Van Thiel DH, Casavilla A, Iwatsuki S, Tzakis A, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 1994; 219 (1):40-45.  Back to cited text no. 3
    
4.
Rerknimitr R, Sherman S, Fogel EL, Kalayci C, Lumeng L, Chalasani N, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc 2002; 55 (2):224-231.  Back to cited text no. 4
    
5.
Thuluvath PJ, Atassi T, Lee J. An endoscopic approach to biliary complications following orthotopic liver transplantation. Liver Int 2003; 23 (3):156-162.  Back to cited text no. 5
    
6.
Thethy S, Thomson BNJ, Pleass H, Wigmore SJ, Madhavan K, Akyol M, et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 2004; 18 (6):647-653.  Back to cited text no. 6
    
7.
Seehofer D, Eurich D, Veltzke-Schlieker W, Neuhaus P. Biliary complications after liver transplantation: old problems and new challenges. Am J Transplant 2013; 13 (2):253-265.  Back to cited text no. 7
    
8.
Thuluvath PJ, Pfau PR, Kimmey MB, Ginsberg GG. Biliary complications after liver transplantation: the role of endoscopy. Endoscopy 2005; 37 (9):857-863.  Back to cited text no. 8
    
9.
Davidson BR, Rai R, Kurzawinski TR, Selves L, Farouk M, Dooley JS, et al. Prospective randomized trial of end-to-end versus side-to-side biliary reconstruction after orthotopic liver transplantation. Br J Surg 1999; 86 (4):447-452.  Back to cited text no. 9
    
10.
Park JS, Kim MH, Lee SK, Seo DW, Lee SS, Han J, et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc 2003; 57 (1):78-85.  Back to cited text no. 10
    
11.
Sawyer RG, Punch JD. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation 1998; 66 (9):1201-1207.  Back to cited text no. 11
    
12.
Verdonk RC, Buis CI, Porte RJ, Haagsma EB. Biliary complications after liver transplantation: a review. Scand J Gastroenterol Suppl 2006; (243):89–101.  Back to cited text no. 12
    
13.
Pascher A, Neuhaus P. Biliary complications after deceased-donor orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13 (6):487-496.  Back to cited text no. 13
    
14.
Scatton O, Meunier B, Cherqui D, Boillot O, Sauvanet A, Boudjema K, et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg 2001; 233 (3):432-437.  Back to cited text no. 14
    
15.
Vougas V, Rela M, Gane E, Muiesan P, Melendez HV, Williams R, et al.A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube? Transpl Int 1996; 9:392.  Back to cited text no. 15
    
16.
Amador A, Charco R, Marti J, Alvarez G, Ferrer J, Mans E, et al. Cost/efficacy clinical trial about the use of T-tube in cadaveric donor liver transplant: preliminary results. Transplant Proc 2005; 37 (2):1129-1130.  Back to cited text no. 16
    
17.
Koivusalo A, Isoniemi H, Salmela K, Edgren J, von Numers H, Höckerstedt K. Biliary complications in one hundred adult liver transplantations. Scand J Gastroenterol 1996; 31 (5):506-511.  Back to cited text no. 17
    
18.
Sotiropoulos GC, Sgourakis G, Radtke A, Molmenti EP, Goumas K, Mylona S, et al. Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results. Transplantation 2009; 87 (11):1672-1680.  Back to cited text no. 18
    
19.
Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992; 16 (1):49-53.  Back to cited text no. 19
    
20.
Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Buckel EG, Steers JL, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 1993; 17 (4):605-609.  Back to cited text no. 20
    
21.
Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013;258 (3):409-421.  Back to cited text no. 21
    
22.
Elmunzer BJ, Debenedet AT, Volk ML, Sonnenday CJ, Waljee AK, Fontana RJ, et al. Clinical yield of diagnostic endoscopic retrograde cholangiopancreatography in orthotopic liver transplant recipients with suspected biliary complications. Liver Transpl 2012; 18 (12):1479–1484.  Back to cited text no. 22
    
23.
Tabibian JH, Asham EH, Han S, Saab S, Tong MJ, Goldstein L, et al. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc 2010; 71 (3):505–512.  Back to cited text no. 23
    
24.
Felker ER, Lee-Felker SA, Ajwichai K, Tan N, Lu DS, Durazo FA, Raman SS. Intraductal cooling via a nasobiliary tube during radiofrequency ablation of central liver tumors reduces biliary injuries. Am J Roentgenol 2015; 204 (6):1329–1335.  Back to cited text no. 24
    
25.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366 (6):539–551.  Back to cited text no. 25
    
26.
Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14 (25):3948–3955.  Back to cited text no. 26
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
   Abstract
  Introduction
   Diagnosis and Ad...
  Techniques
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed463    
    Printed2    
    Emailed0    
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]